A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: Case report

Neurosurgery

Volumn 68, Issue 6, 2011, Pages

  Murakami, Mineko ^a   Mizutani, Akiko ^a   Asano, Shuichiro ^a   Katakami, Hideki ^a   Ozawa, Yoshinori ^b   Yamazaki, Kazuto ^a   Ishida, Yasuo ^a   Takano, Koji ^c   Okinaga, Hiroko ^d   Matsuno, Akira ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b CHIBA ROSAI HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

Author keywords

Atypical prolactinoma; Ki 67; MGMT; MSH6; p53; Pituitary carcinoma; Temozolomide

Indexed keywords

BETA INTERFERON; BROMOCRIPTINE; CABERGOLINE; CARBOPLATIN; EOSIN; ETOPOSIDE; HEMATOXYLIN; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROLACTIN; PROTEIN MSH6; PROTEIN P53; TEMOZOLOMIDE;

ADULT; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ARTICLE; BRAIN METASTASIS; BRAIN STEM INJURY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CAVERNOUS SINUS; COMA; CONSCIOUSNESS DISORDER; DISORIENTATION; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEMIANOPIA; HISTOPATHOLOGY; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUTATIONAL ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOMOTOR NERVE DISEASE; OPTIC NERVE ATROPHY; POSTERIOR CRANIAL FOSSA TUMOR; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN PRODUCING PITUITARY CARCINOMA; PROLACTINOMA; QUADRIPLEGIA; RADIATION DOSE; RADIOSURGERY; REOPERATION; SALVAGE THERAPY; SEPSIS; TISSUE SECTION; TRANSSPHENOIDAL SURGERY; TRIGEMINAL NERVE DISEASE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION; UNILATERAL BLINDNESS; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79955890264     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318217161a     Document Type: Article

References (30)

1. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide: report of two cases. J Neurosurg. 2006;105(4): 621-626. (Pubitemid 44525896)
2. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189. (Pubitemid 44880216)
3. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520. (Pubitemid 43796152)
4. Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary. 2007;10(1):81-86. (Pubitemid 46562811)
5. Syro LV, Uribe H, Penagos LC, et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf). 2006;65(4):552-553. (Pubitemid 44414285)
6. McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226-233.
7. Byrne S, Karapetis C, Vrodos N. A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci. 2009;16(12):1694-1696.
8. Guzel A, Tatli M, Senturk S, Guzel E, Cayli SR, Sav A. Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol. 2008;23 (12):1467-1471.
9. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009; 64(4):E773-E774.
10. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-637.
11. Takeshita A, Inoshita N, Taguchi M, et al. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol. 2009;161(4):553-559.
12. Moyes VJ, Alusi G, Sabin HI, et al. Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol. 2009;160(1):115-119.
13. Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115(2):261-262.
14. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004; 10(6):1871-1874. (Pubitemid 38375541)
15. Hegi M, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
16. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793-797. (Pubitemid 29086728)
17. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96(3):766-776.
18. Branch P, Aquilina G, BignamiM, Karran P.Defectivemismatch binding and amutator phenotype in cells tolerant to DNA damage. Nature. 1993;362(6421):652- 654. (Pubitemid 23109278)
19. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea. Cancer Res. 1996;56(23):5375-5379. (Pubitemid 27011367)
20. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987-3991.
21. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13(17):2038-2045. (Pubitemid 46649870)
22. Widhalm G, Wolfsberger S, Preusser M, et al. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer. 2009;115(5):1070-1080.
23. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38(4):765-770.
24. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089-3099. (Pubitemid 40686369)
25. Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol. 2007;18(4):217-222.
26. Kawashima ST, Usui T, Sano T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf). 2009;70(4): 656-657.
27. Pinto EM, Siqueira SA, Cukier P, Fragoso MC, Lin CJ, de Mendonca BB. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome [published online ahead of print August 5, 2009]. Pituitary. doi: 10.1007/s11102-009-0194-y.
28. Umar A, KoiM, Risinger JI, et al. Correction of hypermutability, N-methyl-N#-nitro- N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 1997;57(18):3949-3955. (Pubitemid 27427682)
29. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18): 1851-1860.
30. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751-2763. (Pubitemid 43974193)